Skip to main content
Premium Trial:

Request an Annual Quote

XDx, LabCorp Expand AlloMap Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that it has entered into a multi-year agreement with Laboratory Corporation of America to provide the firm's AlloMap test in North America.

Under the deal, the molecular expression test will be offered to heart transplant patients, who will be able to have their blood drawn at participating LabCorp sites across the US. In addition, LabCorp will be XDx's preferred third-party, non-hospital provider for phlebotomy and specimen processing for all XDx AlloMap molecular expression tests conducted in North America.

"Those heart transplant recipients eligible for our AlloMap test will enjoy access to and the greater convenience of more than 1,700 patient service centers," Pierre Cassigneul, president and CEO of XDx, said in a statement.

The agreement follows a one-year pilot program at select LabCorp blood draw sites.

Brisbane, Calif.-based XDx said that its reference lab will continue to perform the AlloMap test.

The firm received US Food and Drug Administration clearance in 2008 for the AlloMap test for heart transplant patients. It plans to pursue development of other gene expression-based tests for autoimmune diseases including lupus.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.